Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8WYB5
UPID:
KAT6B_HUMAN
Alternative names:
Histone acetyltransferase MOZ2; MOZ, YBF2/SAS3, SAS2 and TIP60 protein 4; Monocytic leukemia zinc finger protein-related factor
Alternative UPACC:
Q8WYB5; O15087; Q86Y05; Q8WU81; Q9UKW2; Q9UKW3; Q9UKX0
Background:
Histone acetyltransferase KAT6B, also known as Histone acetyltransferase MOZ2, plays a pivotal role in transcription regulation, both activating and repressing gene expression. It is essential for RUNX2-dependent transcriptional activation and is implicated in cerebral cortex development as part of the MOZ/MORF complex with histone H3 acetyltransferase activity.
Therapeutic significance:
KAT6B mutations are linked to Ohdo syndrome, SBBYS variant, and Genitopatellar syndrome, involving severe developmental and skeletal abnormalities. Understanding KAT6B's role could lead to targeted therapies for these conditions.